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The application and feasibility of using routine data sources for long term 
cancer clinical trial follow-up 
Introduction 
As cancer-specific survival rates increase, patients are living longer and therefore 
their chances of developing late recurrences and long term side-effects have also 
increased. This recurrence and toxicity data is important for developing the optimal 
management for patients, and also for providing information on long-term 
consequences of treatments as part of the informed consent process.  
Historically, most radiotherapy trials have endeavoured to follow up patients for at 
least 10 years. The need to capture long-term outcome events is clear, but is 
especially pertinent with radiotherapy trials as adverse effects can continue to occur 
and develop years and sometimes decades after completion of treatment.  
Obtaining prolonged clinical trial follow-up is becoming increasingly challenging, 
especially against the background of rising survival rates. In addition, workforce 
changes in cancer care have taken place following national guidance such as the 
2016 NHS England publication “Achieving World Class Cancer Outcomes: Taking 
the strategy forward”(1). This document states that the uptake of risk stratified follow 
up should increase by 2017 and gives the following example: “We know that risk 
stratified follow up pathways for breast cancer patients can not only improve care for 
patients after treatment, but create more efficient pathways in the NHS that can, for 
example, reduce unnecessary outpatient appointments”. The fundamental need to 
obtain long term outcome data within a clinical trial, is therefore slightly at odds with 
the move towards risk stratified follow up. Hospitals who have already streamlined 
follow up may consider additional clinic visits for clinical trial assessment as a 
financial burden and some patients view extra hospital visits negatively. 
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Solutions are required to maintain methods of long term clinical trial follow-up that 
accurately capture outcome data. Routinely collected data from hospitals linked to 
cancer registries may provide some solutions for long term clinical trial follow-up, 
without the need for additional clinic visits as demonstrated by Appleyard et al in this 
Special Issue (). We will build on this concept and discuss preliminary work 
investigating the application and feasibility of using routine data sources for the 
purposes of identifying accuracy of baseline data, recurrence and survival data for 
cancer clinical trial follow-up. 
What is the feasibility of obtaining cancer clinical trial follow-up from routine 
data sources?  
The National Cancer Registration and Analysis Service (NCRAS) are responsible for 
the systematic collection, quality assurance and analysis of cancer registration data 
in England to support cancer epidemiology, public health, service monitoring and 
research. The NCRAS routine datasets may provide valuable information regarding 
baseline patient demographics and characteristics, treatments, safety, survival and 
recurrence data (3).  
Although routine data sources were designed to collate cancer outcome data for 
patients, they were not specifically designed to collect information for use in clinical 
trials and the focus of the NCRAS data is not to support long-term clinical trial follow-
up. Clinical trial related endpoint data may not be easily available in routine data. For 
example, local recurrence is an important endpoint in cancer clinical trials, but the 
Cancer Outcomes and Services Dataset (COSD) does not differentiate between local 
and distant recurrences. In addition, major cardiovascular events may be identifiable, 
but radiotherapy related normal tissue effects (NTEs) would not be available. 
Therefore although NCRAS may provide a vast amount of data, the feasibility of 
using routine data sets for long-term trial follow-up needs assessment. Preliminary 
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work investigating whether routine data can be used for long-term trial follow-up is 
ongoing with several groups.   
TACT- NCDR Retrospective linkage project 
The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) and 
NCRAS have conducted a joint retrospective linkage project comparing routine data 
in the National Cancer Data Repository (NCDR) with the TACT trial 
(ISRCTN:79718493) data (4). The aim of this study was to assess quality and 
completeness of the routine data and to identify the current ability of routine datasets 
to determine cancer trial outcomes as a baseline to determine the feasibility of a 
prospective validation study. Major findings from the TACT-NCDR linkage project 
included (i) lack of standardisation of data collection across registries requiring 
extensive data cleaning and (ii) a large amount of missing data. Of note, patients 
were included in the TACT study over 10 years ago and therefore we would expect 
the registry data available now to be improved with less missing data. A third finding 
was the lack of recurrence data and/or the inability to determine whether this was 
local or systemic. Preliminary work by NCRAS on the development of an algorithm to 
characterise recurrences using routinely collected data has now been done. This 
algorithm requires further refinement and validation which will be conducted by the 
ICR-CTSU in partnership with NCRAS and will now be outlined. 
 
NCRAS Prospective validation study  
Following on from the TACT-NCDR linkage study, the next step is to prospectively 
evaluate the new routine datasets; COSD, Systemic Anti-Cancer Therapy Dataset 
(SACT) and National Radiotherapy Dataset (RTDS) with contemporary trial data. 
This analysis is timely as these datasets are now available for analysis and there is 
an agreement in place for the ICR-CTSU to work together with NCRAS on this study. 
The NCRAS prospective validation study aims to identify whether routine datasets 
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are of sufficient standard to replace traditional data collection methods and also to 
help NCRAS improve their data collection and identify areas of quality concern where 
data collection can be improved. The ICR-CTSU will work with NCRAS to 
prospectively validate COSD, SACT, RTDS and Hospital Episode Statistics (HES) 
datasets using data from four early breast cancer trials TACT2 
(ISRCTN68068041)(5), POETIC (ISRCTN63882543), IMPORT HIGH 
(ISRCTN47437448) and FAST FORWARD (ISRCTN19906132)  deliberately chosen 
to provide a range of time periods of recruitment and treatment modalities. Data will 
be requested and analysed over a period of 5 years in the first instance. (See table) 
The objectives of the prospective validation study include identifying and quantifying 
trial participants within each dataset and assessing the completeness, validity and 
consistency of routine data with trial data. In particular, time to tumour recurrence, 
overall, disease-free and relapse-free survival, time to loco-regional and distant 
recurrence and long term safety/ comorbidity data in TACT2 and POETIC and local 
control, relapse and disease free survival, time to distant metastases and late 
adverse effects in IMPORT HIGH and FAST FORWARD. A cross comparison of trial 
baseline and treatment data and emerging disease related outcome data with routine 
data will also be undertaken. Long-term safety data will be collected and the 
representativeness of trial patients versus the general population identified. Once the 
project is fully established the plan is to extend beyond breast cancer into other 
disease sites including bladder and prostate cancers.  
Prospective validation of routine data in recruiting studies 
In addition to prospectively validating routine cancer registry data with trial data from 
completed studies, mechanisms for collecting data directly from cancer registry data 
in recruiting studies will be established within the ICR-CTSU. In the PRIMETIME 
(ISRCTN: 41579286) (6) ‘Post-operative avoidance of radiotherapy: biomarker 
selection of women categorised to be in a very low risk group by IHC4+C’ in early 
5 
 
breast cancer study, data (including local, distant relapse, new primary cancers, 
death, cause of death) will be collected from routine data sources. These routine 
data sources will include COSD, RTDS, SACT, HES, the Office for National Statistics 
(ONS) mortality file and the equivalent databases in the devolved nations. These 
datasets will be used to compare routine data collection with the traditional data 
collection methods to identify ipsilateral breast local relapse. Six monthly data 
downloads will be received from NCRAS. One of the main objectives in PRIMETIME 
is to obtain routine data regularly and with a quick turnaround to identify if we are 
able to detect events from the routine data sources in ‘real time’. If routine data is 
used in place of traditional data collection methods the routine data needs to be 
frequently updated and any lag periods avoided. The time spent requesting, 
receiving and processing routine data will need to be reduced as much as possible to 
avoid delays in detecting an outcome which could compromise trial reporting. 
 
Conclusion 
Routine NHS cancer data may provide a source of baseline, recurrence, survival and 
toxicity data for clinical trial follow-up and the feasibility of this application is under 
investigation. The TACT-NCDR retrospective linkage study demonstrated the need 
for standardisation of data collection and extensive data cleaning. Further 
improvements may be demonstrated following an increase in cancer registry data 
quality and development of an algorithm to characterise recurrences. This will be 
assessed within the ongoing NCRAS prospective validation study and will give 
insight as to whether routine datasets are of sufficient standard to replace traditional 
data collection methods. In addition, validation and refinement of the algorithm to 
characterise recurrences may allow discrimination between local and distant 
recurrences from routine data sources. Future challenges such as collection of long 
term toxicity data are ongoing, but by working in partnership with Public Health 
England and NCRAS we hope to identify which routine data sources are a viable 
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source of long-term follow-up clinical trial data and develop ways of improving data 
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